Merck funds ARVS, Moeti applauds! :: Mmegi Online

Managing director of African Comprehensive HIV/AIDS Partnerships (ACHAP), Dr Themba Moeti, has commended drug maker Merck & Co. Inc on its second phase of funding and donations of Anti Retroviral (ARV) towards addressing the needs of people living with HIV/AIDS in the country.

Moeti registered the compliment last week following an announcement that drug maker, Merck & Co. Inc, and the Bill & Melinda Gates Foundation will commit an additional $60 million to ACHAP. With Tuesday's pledge, the Merck Foundation and the Gates Foundation's total cash contributions now amount to $166.5 million.

"Our partners' contributions, through funding, antiretroviral drugs medicine donations and medical expertise, have been absolutely essential to our ability to address the needs of Batswana living with HIV and AIDS," said Moeti.He added that they look forward to strengthening the partnership as it enters the second phase.

Already have an active account? Log in here.

Or Sign up and get unlimited access to premium articles.

Morupisi: The indefatigable fighter

Explore

More

Merck funds ARVS, Moeti applauds!

Managing director of African Comprehensive HIV/AIDS Partnerships (ACHAP), Dr Themba Moeti, has commended drug maker Merck & Co. Inc on its second phase of funding and donations of Anti Retroviral (ARV) towards addressing the needs of people living with HIV/AIDS in the country.

Monyatsi resigns at Letshego

Morupisi: The indefatigable fighter

The newsroom debate

The real business begins

The landing has not been easy

Insights from BNF’s Molutsi

Sejoe: An epitome of resilience

BDP’s heated race for leadership

Refrain from risky behaviours